Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Medical Instruments & Supplies

West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging products. This segment also provides drug containment solutions in the form of vials, syringes, and cartridges; and self-injection devices; and a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. This segment primarily serves pharmaceutical, diagnostic, and medical device companies. It sells and distributes its products through its sales force and distribution network, contract sales agents, and regional distributors. West Pharmaceutical Services, Inc. was founded in 1923 and is headquartered in Exton, Pennsylvania.

Revenue projections:

Revenue projections for WST
Revenue projections for WST

WST's projected revenue decline from last year is likely to make investors cautious. Lower revenues often hurt a company's bottom line, leading investors to be concerned about the company's ability to maintain profitability and deliver strong financial results in the future.

Financial Ratios:

currentRatio 3.002000
forwardPE 41.401207
debtToEquity 11.188000
earningsGrowth -0.136000
revenueGrowth -0.001000
grossMargins 0.348700
operatingMargins 0.223190
trailingEps 6.730000
forwardEps 7.520000

WST's current ratio being 3.002 shows it has more than enough assets to cover its short-term debts. The company's liquidity position is strong, with ample cash reserves available to meet its immediate financial obligations without strain.
WST's low Debt-to-Equity ratio demonstrates that the company is not over-leveraged. This means it maintains a healthy balance between debt and equity, lowering financial risk and contributing to overall financial stability, which could attract risk-averse investors.
West Pharmaceutical Services, Inc.'s low earnings and revenue growth suggest that the company's profits may shrink. This trend could indicate underlying financial struggles and pose challenges for West Pharmaceutical Services, Inc.'s future profitability.
West Pharmaceutical Services, Inc.'s positive gross and operating margins suggest that the company is operating profitably. These strong margins indicate effective cost management and revenue generation, contributing to a solid financial foundation.
With WST's forward EPS higher than its trailing EPS, the company is expected to be more profitable in the current financial year. This signals confidence in WST's growth potential, as improved earnings are forecasted compared to the prior year's performance.

Price projections:

Price projections for WST
Price projections for WST

WST's price has consistently hovered around the lower limit of price projections. This pattern suggests that the stock may be underperforming relative to expectations, which could lead to concerns among investors.

Recommendation changes over time:

Recommendations trend for WST
Recommendations trend for WST


The analysts' recent buy bias for WST indicates strong confidence in the stock's future performance. This could encourage more investors to view WST as a worthwhile investment, positioning the company as a top choice for those seeking financial security and long-term growth opportunities.